This study will evaluate the benefits and costs of methotrexate therapy in rheumatoid arthritis utilizing data collected annually since 1983 from a panel of RA patients in Northern California. The specific research goals include: l) Determine the efficacy of methotrexate treatment among patients treated continuously with MTX for several years. 2) Estimate a model of the factors that predict the response to methotrexate. The role of patient characteristics such as age, sex, duration of illness, medication history, comorbidities, concurrent medications, prior clinical course, and psychosocial factors will be investigated. 3) Determine the rate of discontinuation of methotrexate, and describe the specific reasons for discontinuation including lack of efficacy and toxicity. 4) Determine the cost- effectiveness of methotrexate (MTX) added to standard therapy. The costs of health care will be estimated from annual data reflecting the utilization of health care services. Outcome will be estimated from data reflecting functional status, severity of disease symptoms, and treatment side effects. 5) Determine the relative cost-effectiveness of MTX compared to other medications used in the routine management of these RA patients using similar methods to determine the efficacy, toxicity, and costs of other medical therapies. A multivariate model will be used to determine the effect of MTX treatment after adjusting for covariates which have an important impact on the course of illness. Information collected from both patients and physicians will be utilized to determine the average rate of discontinuation of MTX, and reasons for discontinuation. A multivariate model will be used to determine the effect of MTX treatment on costs incurred after adjusting for covariates which have a significant impact on costs.

Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Briggs, F B S; Ramsay, P P; Madden, E et al. (2010) Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis. Genes Immun 11:199-208
Yazdany, Jinoos; Yelin, Edward (2010) Health-related quality of life and employment among persons with systemic lupus erythematosus. Rheum Dis Clin North Am 36:15-32, vii
Janssens, A Cecile J W; Steyerberg, Ewout W; Jiang, Yebin et al. (2006) Value of the HLA-DRB1 shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile. J Rheumatol 33:2383-9
Katz, Patricia P (2006) Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum 55:217-23
Yelin, Edward H; Trupin, Laura S; Katz, Patricia P (2005) Impact of managed care on the use of biologic agents for rheumatoid arthritis. Arthritis Rheum 53:423-30
Katz, Patricia P (2005) Use of self-management behaviors to cope with rheumatoid arthritis stressors. Arthritis Rheum 53:939-49
von Scheven, E; Elder, M E (2005) Association between beta2-glycoprotein I gene polymorphisms and pediatric SLE and antiphospholipid antibodies. Lupus 14:440-4
Yang, Nan; Li, Hongzhe; Criswell, Lindsey A et al. (2005) Examination of ancestry and ethnic affiliation using highly informative diallelic DNA markers: application to diverse and admixed populations and implications for clinical epidemiology and forensic medicine. Hum Genet 118:382-92
Seldin, Michael F; Morii, Takanobu; Collins-Schramm, Heather E et al. (2004) Putative ancestral origins of chromosomal segments in individual african americans: implications for admixture mapping. Genome Res 14:1076-84
Chang, Wenhan; Shoback, Dolores (2004) Extracellular Ca2+-sensing receptors--an overview. Cell Calcium 35:183-96

Showing the most recent 10 out of 111 publications